Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?H Bonnefoi, S Diebold-Berger, P Therasse, et al.
ESMO Open|June 27, 2022
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapyC Blaye, É Darbo, M Debled, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2012
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancerH Bonnefoi, K Zaman, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancerC Criscitiello, M A Bayar, G Curigliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2007
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006M Kaufmann, G von Minckwitz, H D Bear, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyH Bonnefoi, W Jacot, M Saghatchian, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2003
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)R E N van Rijswijk, J B Vermorken, N Reed, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)H Bonnefoi, T Grellety, O Tredan, et al.
Pageof 5